Novo Nordisk has agreed to pay up to $1.3 billion to license and develop Nanexa's drug delivery technology, in a deal aimed at cutting how often patients inject its obesity and diabetes drugs, The Wall Street Journal reports.

The agreement covers Nanexa's PharmaShell platform, an ultra-thin coating applied to individual drug particles that enables controlled and sustained release of active pharmaceutical ingredients. Under the exclusive arrangement, Novo Nordisk licensed the Swedish company's technology in up to five development programs covering different administration frequencies. The companies are targeting monthly and quarterly dosing — a meaningful shift for a portfolio currently built on weekly injection schedules.

For R&D managers, the economics are straightforward. Reduced injection frequency is one of the few remaining levers for differentiation in the GLP-1 market as oral formulations and competing delivery approaches crowd the pipeline. A monthly or quarterly regimen could improve adherence in obesity and type 2 diabetes populations, where drop-off over long treatment horizons is a persistent commercial and clinical problem. The $1.3 billion headline is a ceiling, not a payment: it presumably spans upfront fees, milestones and royalties across the five programs, though the parties did not break down the structure in the announcement as reported.

The deal also signals how large pharma is sourcing formulation innovation externally. Sustained-release coating technology is the kind of capability that sits outside most big-company core competencies, and Nanexa — a small-cap listed developer — now has a validation event that will likely shape licensing negotiations across the long-acting injectables space.

FDA nominee gives senators little to work with

The week's other headline development played out in Washington. Heidi Overton, President Trump's nominee to lead the U.S. Food and Drug Administration, appeared before the Senate committee that will decide whether to advance her nomination to a full Senate vote. As STAT reports, senators pressed her on China, vaccines and abortion access — but she revealed very little of her own position on the issues facing the agency.

Instead, Overton referred repeatedly to existing agency guidance and approvals, including those covering childhood vaccines and the abortion drug mifepristone. She declined to say whether she would endorse updating those guidances or altering approvals to satisfy the preferences of Trump or Health and Human Services Secretary Robert F. Kennedy Jr.

The reticence leaves R&D planning teams without new signal. For sponsors with pending applications or programs that depend on vaccine and reproductive-health review pathways, the hearing offered no indication of how the nominee would steer the agency's scientific staff, guidance revision processes or review timelines if confirmed. Confirmation by the full Senate remains the next formal step.

Nanexa investors reacted to the Novo deal as the week closed, and the FDA nomination now moves to the Senate floor, where the vote will determine who sets the agency's agenda through the remainder of the administration's term.